Journal
DRUGS
Volume 77, Issue 13, Pages 1487-1492Publisher
ADIS INT LTD
DOI: 10.1007/s40265-017-0800-7
Keywords
-
Categories
Ask authors/readers for more resources
Guselkumab (Tremfya (TM)) is a human monoclonal IgG1 lambda antibody being developed by Janssen Biotech, Inc. that has been approved in the USA as a treatment for moderate-to-severe plaque psoriasis. Guselkumab inhibits the binding of interleukin 23 (IL-23) to its cell surface receptor, disrupting the type 17 helper T cell/IL-17 pathway. This article summarizes the milestones in the development of guselkumab leading to this first approval for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available